There is currently an unmet clinical need for a diagnostic biomarker to predict response to anti-VEGF treatment in DME. In this pilot study, Asst. Prof Su and team performed a systematic comparison of the miRNA profiles generated from tears, aqueous, and serum and identified potential miRNAs in tears to differentiate between responders and suboptimal responders to anti-VEGF therapy. They reported novel miRNAs and provided insight into biological pathways implicated in DME. In addition, they identified tears as a non-invasive source of biofluid to discover novel miRNA biomarkers. Further validation studies in larger independent cohorts are needed to determine the predictive performance of these miRNA candidate biomarkers prior to establishing a panel for use in clinical practice.
In this webinar, we speak with Asst. Prof Su to find out more about her interesting study.